Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Disease Areas » Cancer » Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors

May 16, 2019
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Pediatric cancer patients with a variety of tumors harboring NTRK, ROS1, and ALK alterations saw their tumors shrink after treatment with entrectinib, an investigational drug Roche is studying in a pan-cancer indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Jul
29
Featured Webinar

Life Science Marketing Workshop: Creating a Go-To-Market Strategy in a Rapidly Evolving Sector

Sponsored by
Illumina

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

    Premium

  2. Cancer AI Startup Nucleai Raises $6.5M in Series A Financing

  3. Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

  4. Cancer Research UK, Abcam Partner to Develop Custom Antibodies for Cancer Research

  5. OncoCyte Downgraded to Neutral by Piper Sandler on Unsuccessful Results for Lung Cancer Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.